A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 38/48 (2006.01) A61P 9/10 (2006.01) C07K 16/38 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2344317
The present invention relates to a new means for the treatment of focal ischemic cerebral infarction (ischemic stroke). It has been found that reduction of .alpha.2-antiplasmin leads to a significantly smaller focal cerebral infarct size. The invention therefore provides the use of compounds that reduce .alpha.2-antiplasmin concentration or activity in vivo, for the preparation of a therapeutical composition for the treatment of focal cerebral ischemic infarction (ischemic stroke).
La présente invention concerne un nouveau moyen de traitement de l'infarctus cérébral ischémique focal (accident ischémique cérébral). On a remarqué que la réduction des .alpha.¿2?-antiplasmines provoque une réduction importante de la taille de l'infarctus cérébral focal. Par conséquent, cette invention concerne l'utilisation de composés qui réduisent la concentration ou l'activité in vivo des .alpha.¿2?-antiplasmines, pour la préparation d'une composition thérapeutique destinée à traiter l'infarctus cérébral ischémique focal (accident ischémique cérébral).
Collen Desire Jose
Nagai Nobuo
Fetherstonhaugh & Co.
Leuven Research & Development Vzw
LandOfFree
Use of compounds that reduce alpha2-antiplasmin in vivo for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of compounds that reduce alpha2-antiplasmin in vivo for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of compounds that reduce alpha2-antiplasmin in vivo for... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1862665